View of 938 – TROFUSE-011: a phase 3, randomized, open‑label study of sacituzumab tirumotecan with or without pembrolizumab versus treatment of the physician’s choice for previously untreated, locally recurrent, unresectable, or metastatic triple‑negative breast

Return to Article Details 938 – TROFUSE-011: a phase 3, randomized, open‑label study of sacituzumab tirumotecan with or without pembrolizumab versus treatment of the physician’s choice for previously untreated, locally recurrent, unresectable, or metastatic triple‑negative breast Download Download PDF